ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
1Department of Pharmacology & Toxicology, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Abstract:
Advances in chromosomally rearranged ALK positive non-small cell lung cancer have been dramatic in only the last few years. Survival times have improved dramatically due to the introduction of ever more efficacious ALK inhibitors. These improvements have been due largely to improvements in blood-brain barrier penetration and the breadth of ligand binding pocket mutations against which the drugs are effective. However, the advances maybe slow due to the frequency of cancers with compound resistance mutations are appearing, suggesting the need to develop multiple ALK inhibitors to target different compound mutations.Another research area that promises to provide further gains is the use of drug combinations, with an ALK inhibitor combined with a drug targeting a "second driver" to overcome resistance. In this review, the range of secondary targets for ALK+ lung cancer and the potential for their clinical success are reviewed.
Insights
New ALK inhibitors have greatly improved survival for ALK-positive non-small cell lung cancer. Future progress may involve targeting compound resistance mutations and exploring drug combinations with second drivers.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- ALK-positive non-small cell lung cancer (NSCLC) treatment has seen significant progress.
- Efficacious ALK inhibitors have dramatically improved patient survival times.
- Improvements are linked to enhanced blood-brain barrier penetration and broader efficacy against ALK mutations.
Purpose of the Study:
- To review secondary targets for ALK-positive lung cancer.
- To assess the clinical potential of targeting resistance mechanisms.
- To discuss strategies for overcoming acquired resistance to ALK inhibitors.
Main Methods:
- Literature review of recent advancements in ALK-positive NSCLC.
- Analysis of emerging resistance mutations and their clinical implications.
- Evaluation of drug combination strategies targeting secondary drivers.
Main Results:
- Compound resistance mutations are increasingly frequent, potentially slowing therapeutic advances.
- Development of multiple ALK inhibitors is needed to address diverse resistance profiles.
- Drug combinations, pairing ALK inhibitors with agents targeting second drivers, show promise for overcoming resistance.
Conclusions:
- Continued progress in ALK-positive NSCLC requires addressing compound resistance.
- Targeting secondary drivers in combination therapy is a promising strategy.
- Further research into novel therapeutic targets and combinations is essential.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers